Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: A randomised trial

International Journal of Clinical Practice

Volumn 62, Issue 6, 2008, Pages 919-924

  Anastasilakis, A D ^a,e   Goulis, D G ^b   Polyzos, S A ^a   Gerou, S ^c   Koukoulis, G N ^d   Efstathiadou, Z ^a   Kita, M ^a   Avramidis, A ^a  

^a Aristotle University and Hippokration General Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Laboratories Analysis   (Greece)

^d UNIVERSITY OF THESSALY   (Greece)

^e NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE PAIN; BONE TURNOVER; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIGASTRIC PAIN; FEMALE; FLUSHING; HUMAN; HYPERCALCEMIA; INCIDENCE; KIDNEY COLIC; LUMBAR SPINE; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBSTERNAL BURN;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; ETIDRONIC ACID; FEMALE; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE;

EID: 43749087111     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01768.x     Document Type: Article

References (41)

1. Chen J, Cameron I, Cumming R et al. Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 2006 21 : 324 31.
2. Wolinsky F, Fitzgerald J, Stump T. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 1997 87 : 398 403.
3. Watts N. Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA). Osteoporos Int 2004 15 : 847 54.
4. Sambrook P, Cooper C. Osteoporosis. Lancet 2006 367 : 2010 8.
5. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998 19 : 80 100.
6. Nenonen A, Cheng S, Ivaska K et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005 20 : 1804 12.
7. Rosen H, Moses A, Garber J et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000 66 : 100 3.
8. Hodsman A, Bauer D, Dempster D et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005 26 : 688 703.
9. Orwoll E, Scheele W, Paul S et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003 18 : 9 17.
10. Body J, Gaich G, Scheele W et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002 87 : 4528 35.
11. Chen P, Satterwhite J, Licata A et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005 20 : 962 70.
12. Eastell R, Krege J, Chen P et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006 22 : 61 6.
13. Fink E, Cormier C, Steinmetz P et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000 11 : 295 303.
14. Dobnig H, Hofbauer L, Viereck V et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006 17 : 693 703.
15. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000 26 : 505 11.
16. Greenspan S, Rosen H, Parker R. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000 85 : 3537 40.
17. Rosen C, Hochberg M, Bonnick S et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005 20 : 141 51.
18. Woitge H, Pecherstorfer M, Li Y et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999 14 : 792 801.
19. Eastell R, Barton I, Hannon R et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003 18 : 1051 6.
20. Tahtela R, Seppanen J, Laitinen K et al. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int 2005 16 : 1109 16.
21. McClung M, San Martin J, Miller P et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005 165 : 1762 8.
22. Woitge H, Seibel M, Ziegler R. Comparison of total and bone specific alkaline phosphatase in skeletal and non-skeletal diseases. Clin Chem 1996 42 : 1796 804.
23. Maalouf N, Heller H, Odvina C et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006 12 : 48 53.
24. Zegels B, Eastell R, Russell R et al. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Bone 2001 28 : 108 12.
25. Deal C, Omizo M, Schwartz E et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005 20 : 1905 11.
26. Black D, Greenspan S, Ensrud K et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 349 : 1207 15.
27. Black D, Bilezikian J, Ensrud K et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005 353 : 555 65.
28. Kinyamu H, Gallagher J, Petranick K et al. Effect of parathyroid hormone (hPTH[1-34]) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women. J Bone Miner Res 1996 11 : 1400 5.
29. Cosman F, Shen V, Herrington B et al. Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay. J Clin Endocrinol Metab 1991 73 : 1345 51.
30. Harris S, Watts N, Genant H et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999 282 : 1344 52.
31. Heaney R, Zizic T, Fogelman I et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002 13 : 501 5.
32. Neer R, Arnaud C, Zanchetta J et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 344 : 1434 41.
33. Cifuentes M, Johnson M, Lewis R et al. Bone turnover and body weight relationships differ in normal-weight compared with heavier postmenopausal women. Osteoporos Int 2003 14 : 116 22.
34. Ricci T, Heymsfield S, Pierson RJ et al. Moderate energy restriction increases bone resorption in obese postmenopausal women. Am J Clin Nutr 2001 73 : 347 52.
35. Panidis D, Balaris C, Farmakiotis D et al. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 2005 51 : 1691 7.
36. Clowes J, Peel N, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004 89 : 1117 23.
37. Papaioannou A, Ioannidis G, Adachi J et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003 14 : 808 13.
38. Arden N, Earl S, Fisher D et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006 17 : 1626 9.
39. Cramer J, Amonkar M, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005 21 : 1453 60.
40. McCombs J, Thiebaud P, McLaughlin-Miley C et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004 48 : 271 87.
41. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003 14 : 259 62.